|
1
|
Duncan JD, Urbanowicz RA, Tarr AW and Ball
JK: Hepatitis C Virus vaccine: Challenges and prospects. Vaccines
(Basel). 8(90)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ramsay J, Marsh J, Pedrana A, Andric N,
Norman R, Cheng W, Webb S, Zeps N, Bellgard M, Graves T, et al: A
platform in the use of medicines to treat chronic hepatitis C
(PLATINUM C): Protocol for a prospective treatment registry of
real-world outcomes for hepatitis C. BMC Infect Dis.
20(802)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Falade-Nwulia O, Suarez-Cuervo C, Nelson
DR, Fried MW, Segal JB and Sulkowski MS: Oral direct-acting agent
therapy for hepatitis C virus infection: A systematic review. Ann
Intern Med. 166:637–648. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Li D, Huang Z and Zhong J: Hepatitis C
virus vaccine development: Old challenges and new opportunities.
Natl Sci Rev. 2:285–295. 2015.
|
|
5
|
Forns X, Bukh J and Purcell RH: The
challenge of developing a vaccine against hepatitis C virus. J
Hepatol. 37:684–695. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Buonaguro L, Tagliamonte M, Tornesello ML
and Buonaguro FM: Developments in virus-like particle-based
vaccines for infectious diseases and cancer. Expert Rev Vaccines.
10:1569–1583. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Murata K, Lechmann M, Qiao M, Gunji T,
Alter HJ and Liang TJ: Immunization with hepatitis C virus-like
particles protects mice from recombinant hepatitis C virus vaccinia
infection. Proc Natl Acad Sci USA. 100:6753–6758. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Christiansen D, Earnest-Silveira L,
Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E,
Drummer HE, Gowans EJ and Torresi J: Pre-clinical evaluation of a
quadrivalent HCV VLP vaccine in pigs following microneedle
delivery. Sci Rep. 9(9251)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gastaminza P, Dryden KA, Boyd B, Wood MR,
Law M, Yeager M and Chisari FV: Ultrastructural and biophysical
characterization of hepatitis C virus particles produced in cell
culture. J Virol. 84:10999–11009. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Matsuura Y, Harada S, Suzuki R, Watanabe
Y, Inoue Y, Saito I and Miyamura T: Expression of processed
envelope protein of hepatitis C virus in mammalian and insect
cells. J Virol. 66:1425–1431. 1992.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Baumert TF, Ito S, Wong DT and Liang TJ:
Hepatitis C virus structural proteins assemble into virus like
particles in insect cells. J Virol. 72:3827–3836. 1998.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mihailova M, Boos M, Petrovskis I, Ose V,
Skrastina D, Fiedler M, Sominskaya I, Ross S, Pumpens P, Roggendorf
M and Viazov S: Recombinant virus-like particles as a carrier of B-
and T-cell epitopes of hepatitis C virus (HCV). Vaccine.
24:4369–4377. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Beaumont E, Patient R, Hourioux C,
Dimier-Poisson I and Roingeard P: Chimeric hepatitis B
virus/hepatitis C virus envelope proteins elicit broadly
neutralizing antibodies and constitute a potential bivalent
prophylactic vaccine. Hepatology. 57:1303–1313. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Denis J, Majeau N, Acosta-Ramirez E,
Savard C, Bedard MC, Simard S, Lecours K, Bolduc M, Pare C, Willems
B, et al: Immunogenicity of papaya mosaic virus-like particles
fused to a hepatitis C virus epitope: Evidence for the critical
function of multimerization. Virology. 363:59–68. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chua BY, Johnson D, Tan A,
Earnest-Silveira L, Sekiya T, Chin R, Torresi J and Jackson DC:
Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting
lipopeptide results in enhanced antibody and cell-mediated
responses. PLoS One. 7(e47492)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Qiao M, Murata K, Davis AR, Jeong SH and
Liang TJ: Hepatitis C virus-like particles combined with novel
adjuvant systems enhance virus-specific immune responses.
Hepatology. 37:52–59. 2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Acosta-Rivero N, Poutou J,
Alvarez-Lajonchere L, Guerra I, Aguilera Y, Musacchio A, Rodríguez
A, Aguilar JC, Falcon V, Alvarez-Obregon JC, et al: Recombinant in
vitro assembled hepatitis C virus core particles induce strong
specific immunity enhanced by formulation with an oil-based
adjuvant. Biol Res. 42:41–56. 2009.PubMed/NCBI
|
|
18
|
Logan M, Law J, Wong JAJ, Hockman D, Landi
A, Chen C, Crawford K, Kundu J, Baldwin L, Johnson J, et al: Native
folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from
a precursor protein fused with Fc IgG. J Virol. 91:e01552–16.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Krapchev VB, Rychlowska M, Chmielewska A,
Zimmer K, Patel AH and Bienkowska-Szewczyk K: Recombinant
flag-tagged E1E2 glycoproteins from three hepatitis C virus
genotypes are biologically functional and elicit cross-reactive
neutralizing antibodies in mice. Virology. 519:33–41.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Owsianka AM, Timms JM, Tarr AW, Brown RJ,
Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH
and Ball JK: Identification of conserved residues in the E2
envelope glycoprotein of the hepatitis C virus that are critical
for CD81 binding. J Virol. 80:8695–8704. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tzarum N, Wilson IA and Law M: The
neutralizing face of hepatitis C Virus E2 envelope glycoprotein.
Front Immunol. 9(1315)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kumar A, Hossain RA, Yost SA, Bu W, Wang
Y, Dearborn AD, Grakoui A, Cohen JI and Marcotrigiano J: Structural
insights into hepatitis C virus receptor binding and entry. Nature.
598:521–525. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Desombere I, Fafi-Kremer S, Van Houtte F,
Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, Mckeating JA,
Leroux-Roels G, et al: Monoclonal anti-envelope antibody AP33
protects humanized mice against a patient-derived hepatitis C virus
challenge. Hepatology. 63:1120–1134. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang Y, Keck ZY and Foung SK: Neutralizing
antibody response to hepatitis C virus. Viruses. 3:2127–2145.
2011.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Keck ZY, Saha A, Xia J, Wang Y, Lau P,
Krey T, Rey FA and Foung SK: Mapping a region of HCV E2 that is
responsible for escape from neutralizing antibodies and a core
CD81-binding region that does not tolerate neutralization escape
mutations. J Virol. 85:10451–10463. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Guest JD and Pierce BG: Structure-based
and rational design of a hepatitis C Virus vaccine. Viruses.
13(837)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Pierce BG, Keck ZY, Wang R, Lau P,
Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri
P, et al: Structure-based design of hepatitis C Virus E2
glycoprotein improves serum binding and cross-neutralization. J
Virol. 94:e00704–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kachko A, Frey SE, Sirota L, Ray R, Wells
F, Zubkova I, Zhang P and Major ME: Antibodies to an interfering
epitope in hepatitis C virus E2 can mask vaccine-induced
neutralizing activity. Hepatology. 62:1670–1682. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang P, Zhong L, Struble EB, Watanabe H,
Kachko A, Mihalik K, Virata ML, Alter HJ, Feinstone S and Major M:
Depletion of interfering antibodies in chronic hepatitis C patients
and vaccinated chimpanzees reveals broad cross-genotype
neutralizing activity. Proc Natl Acad Sci USA. 106:7537–7541.
2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ruwona TB, Giang E, Nieusma T and Law M:
Fine mapping of murine antibody responses to immunization with a
novel soluble form of hepatitis C virus envelope glycoprotein
complex. J Virol. 88:10459–10471. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Vietheer PT, Boo I, Gu J, McCaffrey K,
Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P
and Drummer HE: The core domain of hepatitis C virus glycoprotein
E2 generates potent cross-neutralizing antibodies in guinea pigs.
Hepatology. 65:1117–1131. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
McCaffrey K, Boo I, Owczarek CM, Hardy MP,
Perugini MA, Fabri L, Scotney P, Poumbourios P and Drummer HE: An
optimized hepatitis C virus E2 glycoprotein core adopts a
functional homodimer that effciently blocks virus entry. J Virol.
91:e01668–16. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
McCaffrey K, Boo I, Poumbourios P and
Drummer HE: Expression and characterization of a minimal hepatitis
C virus glycoprotein E2 core domain that retains CD81 binding. J
Virol. 81:9584–9590. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li D, von Schaewen M, Wang X, Tao W, Zhang
Y, Li L, Heller B, Hrebikova G, Deng Q, Ploss A, et al: Altered
glycosylation patterns increase immunogenicity of a subunit
hepatitis C virus vaccine, inducing neutralizing antibodies which
confer protection in mice. J Virol. 90:10486–10498. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Urbanowicz RA, Wang R, Schiel JE, Keck ZY,
Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, et
al: Antigenicity and immunogenicity of differentially glycosylated
hepatitis C virus E2 envelope proteins expressed in mammalian and
insect Cells. J Virol. 93:e01403–18. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Naarding MA, Falkowska E, Xiao H and
Dragic T: Hepatitis C virus soluble E2 in combination with QuilA
and CpG ODN induces neutralizing antibodies in mice. Vaccine.
29:2910–2917. 2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Frey SE, Houghton M, Coates S, Abrignani
S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, et
al: Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with
MF59 administered to healthy adults. Vaccine. 28:6367–6373.
2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wedemeyer H, Schuller E, Schlaphoff V,
Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M,
Zeuzem S, et al: Therapeutic vaccine IC41 as late add-on to
standard treatment in patients with chronic hepatitis C. Vaccine.
27:5142–5151. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sarobe P, Pendieton CD, Akatsuka T, Lau D,
Engelhard VH, Feinstone SM and Berzofsky JA: Enhanced in vitro
potency and in vivo immunogenicity of a CTL epitope from hepatitis
C virus core protein following amino acid replacement at secondary
HLA-A2.1 binding positions. J Clin Invest. 102:1239–1248.
1998.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Filskov J, Mikkelsen M, Hansen PR,
Christensen JP, Thomsen AR, Andersen P, Bukh J and Agger EM:
Broadening CD4+ and CD8+ T cell responses
against hepatitis C virus by vaccination with NS3 overlapping
peptide panels in cross-priming liposomes. J Virol. 91:e00130–17.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Filskov J, Andersen P, Agger EM and Bukh
J: HCV p7 as a novel vaccine-target inducing multifunctional
CD4+ and CD8+ T-cells targeting liver cells
expressing the viral antigen. Sci Rep. 9(14085)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Firbas C, Boehm T, Buerger V, Schuller E,
Sabarth N, Jilma B and Klade CS: Immunogenicity and safety of
different injection routes and schedules of IC41, a Hepatitis C
virus (HCV) peptide vaccine. Vaccine. 28:2397–2407. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Firbas C, Jilma B, Tauber E, Buerger V,
Jelovcan S, Lingnau K, Buschle M, Frisch J and Klade CS:
Immunogenicity and safety of a novel therapeutic hepatitis C virus
(HCV) peptide vaccine: A randomized, placebo controlled trial for
dose optimization in 128 healthy subjects. Vaccine. 24:4343–4353.
2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Klade CS, Wedemeyer H, Berg T, Hinrichsen
H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger
V, et al: Therapeutic vaccination of chronic hepatitis C
nonresponder patients with the peptide vaccine IC41.
Gastroenterology. 134:1385–1395. 2008.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yin D, Qi ZT, Yan S, Ding H, Hua X, Tong
YM, Wang YZ, Liu Y, Xu FH and Zhao P: Study on the induction of
mouse neutralization antibodies to HCVpp by HCV E2 DNA vaccines.
Chin J Exp Clin Infect Dis (Electronic Version). 2:24–32. 2008.(In
Chinese).
|
|
46
|
National Institute of Allergy and
Infectious Diseases (NIH): Trial Evaluating Experimental Hepatitis
C Vaccine Concludes. NIH, Bethesda, MD, 2019. https://www.niaid.nih.gov/news-events/trial-evaluating-experimental-hepatitis-c-vaccine-concludes.
Accessed July 8, 2021.
|
|
47
|
Shin EC, Sung PS and Park SH: Immune
responses and immunopathology in acute and chronic viral hepatitis.
Nat Rev Immunol. 16:509–523. 2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lu L, Barbi J and Pan F: The regulation of
immune tolerance by FOXP3. Nat Rev Immunol. 17:703–717.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Langhans B, Nischalke HD, Krämer B, Hausen
A, Dold L, van Heteren P, Hüneburg R, Nattermann J, Strassburg CP
and Spengler U: Increased peripheral CD4+ regulatory T
cells persist after successful direct-acting antiviral treatment of
chronic hepatitis C. J Hepatol. 66:888–896. 2017.PubMed/NCBI View Article : Google Scholar : (In Albanian,
English).
|
|
50
|
Han JW, Sung PS, Hong SH, Lee H, Koh JY,
Lee H, White S, Maslow JN, Weiner DB, Park SH, et al:
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell
frequency and increases virus-specific T-cell responses. J Hepatol.
73:72–83. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wijesundara DK, Gummow J, Li Y, Yu W, Quah
BJ, Ranasinghe C, Torresi J, Gowans EJ and Grubor-Bauk B: Induction
of genotype cross-reactive, hepatitis C virus-specific,
cell-mediated immunity in DNA-vaccinated mice. J Virol.
92:e02133–17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Castellanos M, Cinza Z, Dorta Z, Veliz G,
Vega H, Lorenzo I, Ojeda S, Dueñas-Carrera S, Alvarez-Lajonchere L,
Martínez G, et al: Immunization with a DNA vaccine candidate in
chronic hepatitis C patients is safe, well tolerated and does not
impair immune response induction after anti-hepatitis B
vaccination. J Gene Med. 12:107–116. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Pierce BG, Boucher EN, Piepenbrink KH,
Ejemel M, Rapp CA, Thomas WD Jr, Sundberg EJ, Weng Z and Wang Y:
Structure-based design of hepatitis C virus vaccines that elicit
neutralizing antibody responses to a conserved epitope. J Virol.
91:e01032–17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cowton VM, Owsianka AM, Fadda V,
Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di
Lorenzo C, Dorner M, et al: Development of a structural epitope
mimic: An idiotypic approach to HCV vaccine design. NPJ Vaccines.
6(7)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Choo QL, Kuo G, Ralston R, Weiner A, Chien
D, Van Nest G, Han K, Berger K, Thudium K, Kuo C, et al:
Vaccination of chimpanzees against infection by the hepatitis C
virus. Proc Natl Acad Sci USA. 91:1294–1298. 1994.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Rosa D, Campagnoli S, Moretto C, Guenzi E,
Cousens L, Chin M, Dong C, Weiner AJ, Lau JY, Choo QL, et al: A
quantitative test to estimate neutralizing antibodies to the
hepatitis C virus: Cytofluorimetric assessment of envelope
glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA.
93:1759–1763. 1996.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Shi X, Cao F, Du Y, Hou L, Ji Y and Wang
H: Protein expression and antigenicity detection of Hepatitis C
virus envelope protein E2. Medical Journal of Chinese People's
Liberation Army. 27:17–19. 2002.
|
|
58
|
Dai Z, Li G, Xu Q, Yao L, Han X, Yang L
and Chen W: Expression and Identification of Hepatitis C Virus
Envelop Protein E2. J Sun Yat-Sen Univ (Med Sci). 27:83–89.
2006.(In Chinese).
|
|
59
|
Earnest-Silveira L, Chua B, Chin R,
Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K,
Mesalam A, Meuleman P, et al: Characterization of a hepatitis C
virus-like particle vaccine produced in a human hepatocyte-derived
cell line. J Gen Virol. 97:1865–1876. 2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Earnest-Silveira L, Christiansen D,
Herrmann S, Ralph SA, Das V, Gowans EJ and Torres J: Large scale
production of a mammalian cell derived quadrivalent hepatitis C
virus like particle vaccine. J Virol Methods. 236:87–92.
2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Shu F, Lei YF, Lin F, Wang X, Li B, Zhang
LJ, Dong K, Zhang HZ and Wei SH: Construction of eukaryotic
expression vector for chimeric gene of hepatitis C virus
neutralizing epitopes with hepatitis B virus S antigen and its
expression in 293T cells. Chinese Journal of Biologicals.
26:795–799. 2013.
|
|
62
|
Martínez-Donato G, Capdesuñer Y,
Acosta-Rivero N, Rodríguez A, Morales-Grillo J, Martínez E,
González M, Alvarez-Obregon JC and Dueñas-Carrera S: Multimeric HCV
E2 protein obtained from Pichia pastoris cells induces a strong
immune response in mice. Mol Biotechnol. 35:225–235.
2007.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Yagnik AT, Lahm A, Meola A, Roccasecca RM,
Ercole BB, Nicosia A and Tramontano A: A model for the hepatitis C
virus envelope glycoprotein E2. Proteins. 40:355–366.
2000.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Duvet S, Cocquerel L, Pillez A, Cacan R,
Verbert A, Moradpour D, Eychoeski C and Dubuisson J: Hepatitis C
virus glycoprotein complex localization in the endoplasmic
reticulum involves a determinant for retention and not retrieval. J
Biol Chem. 273:32088–32095. 1998.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Nemchinov LG, Liang TJ, Rifaat MM, Mazyad
HM, Hadidi A and Keith JM: Development of a plant-derived subunit
vaccine candidate against hepatitis C virus. Arch Virol.
145:2557–2573. 2000.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Bolhassani A, Davoudi N, Motevalli F and
Agi E: Comparison of HCV Core and CoreE1E2 virus-like particles
generated by stably transfected leishmania tarentolae for the
Stimulation of Th1 immune responses in mice. Curr Drug Deliv.
14:1040–1049. 2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Kunkel M, Lorinczi M, Rijnbrand R, Lemon
SM and Watowich SJ: Self-assembly of nucleocapsid-like particles
from recombinant hepatitis C virus core protein. J Virol.
75:2119–2129. 2001.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Tarr AW, Backx M, Hamed MR, Urbanowicz RA,
McClure CP, Brown RJP and Ball JK: Immunization with a synthetic
consensus hepatitis C virus E2 glycoprotein ectodomain elicits
virus-neutralizing antibodies. Antivir Res. 160:25–37.
2018.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Cao L, Yu B, Kong D, Cong Q, Yu T, Chen Z,
Hu Z, Chang H, Zhong J, Baker D and He Y: Functional expression and
characterization of the envelope glycoprotein E1E2 heterodimer of
hepatitis C virus. PLoS Pathog. 15(e1007759)2019.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Fazlalipour M, Keyvani H, Monavari SH and
Mollaie HR: Expression, purification and immunogenic description of
a hepatitis C virus recombinant CoreE1E2 protein expressed by yeast
Pichia pastoris. Jundishapur J Microbiol. 8(e17157)2015.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Pechelyulko A, Andreeva-Kovalevskaya Z,
Dmitriev D, Lavrov V, Massino Y, Nagel A, Segal O, Sokolova OS,
Solonin A, Tarakanova Y and Dmitriev A: A simple method to purify
recombinant HCV core protein expressed in Pichia pastoris for
obtaining virus-like particles and producing monoclonal antibodies.
Protein Expr Purif. 183(105864)2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Cai W, Su L, Liao Q, Ye L, Wu Y, Wu Z and
She Y: Expression, purification and immunogenic characterization of
hepatitis C virus recombinant E1E2 protein expressed by Pichia
pastoris yeast. Antivir Res. 88:80–85. 2010.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Martinez-Donato G, Acosta-Rivero N,
Morales-Grillo J, Musacchio A, Vina A, Alvarez C, Figueroa N,
Guerra I, Garcia J, Varas L, et al: Expression and processing of
hepatitis C virus structural proteins in Pichia pastoris yeast.
Biochem Biophys Res Commun. 342:625–631. 2006.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Yao M, Fang H, Yin W, Lei Y, Yang J, Sun
M, Tian J and Lv X: Prokaryotic expression and purification of
truncated Hepatitis C Virus envelope glycoprotein E2. Science
Technology and Engineering,. 9:2296–2303. 2009.
|
|
75
|
Cocquerel L, Meunier JC, Pillez A,
Wychowski C and Dubuisson J: A retention signal necessary and
sufficient for endoplasmic reticulum localization maps to the
transmembrane domain of hepatitis C virus glycoprotein E2. J Virol.
72:2183–2191. 1998.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Cocquerel L, Wychowski C, Minner F, Penin
F and Dubuisson J: Charged residues in the transmembrane domains of
hepatitis C virus glycoproteins play a major role in the
processing, subcellular localization, and assembly of these
envelope proteins. J Virol. 74:3623–3633. 2000.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Matsuura Y, Suzuki T, Suzuki R, Sato M,
Aizaki H, Saito I and Miyamura T: Processing of E1 and E2
glycoproteins of hepatitis C virus expressed in mammalian and
insect cells. Virology. 205:141–150. 1994.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Mizushima H, Hijikata M, Asabe S, Hirota
M, Kimura K and Shimotohno K: Two hepatitis C virus glycoprotein E2
products with different C termini. J Virol. 68:6215–6222.
1994.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Morin TJ, Broering TJ, Leav BA, Blair BM,
Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, et
al: Human monoclonal antibody HCV1 effectively prevents and treats
HCV infection in chimpanzees. PLoS Pathog.
8(e1002895)2012.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Impagliazzo A, Milder F, Kuipers H, Wagner
MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P,
Verspuij J, et al: A stable trimeric influenza hemagglutinin stem
as a broadly protective immunogen. Science. 349:1301–1306.
2015.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Kulp DW, Steichen JM, Pauthner M, Hu X,
Schiffner T, Liguori A, Cottrell CA, Havenar-Daughton C, Ozorowski
G, Georgeson E, et al: Structure-based design of native-like HIV-1
envelope trimers to silence non-neutralizing epitopes and eliminate
CD4 binding. Nat Commun. 8(1655)2017.PubMed/NCBI View Article : Google Scholar
|
